Population Pharmacokinetics and Exposure-Response Analyses of Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma.

The PPK and E-R analyses support the daratumumab subcutaneous 1,800-mg dosing regimen in combination with Pd for treatment of patients with RRMM. No dose adjustment is recommended in this indication for any of the investigated factors, none of which had clinically relevant effects on daratumumab PK.